DE10013318A1 - Formulierung enthaltend Chinoxalinderivate - Google Patents

Formulierung enthaltend Chinoxalinderivate

Info

Publication number
DE10013318A1
DE10013318A1 DE10013318A DE10013318A DE10013318A1 DE 10013318 A1 DE10013318 A1 DE 10013318A1 DE 10013318 A DE10013318 A DE 10013318A DE 10013318 A DE10013318 A DE 10013318A DE 10013318 A1 DE10013318 A1 DE 10013318A1
Authority
DE
Germany
Prior art keywords
quinoxalinyl
groups
optionally
alkyl
het
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE10013318A
Other languages
German (de)
English (en)
Inventor
Frank Pfluecker
Hansjuergen Driller
Michael Kirschbaum
Volker Scholz
Hans Neunhoeffer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Priority to DE10013318A priority Critical patent/DE10013318A1/de
Priority to PCT/EP2001/002517 priority patent/WO2001068047A2/de
Priority to US10/221,726 priority patent/US20030207886A1/en
Priority to EP01909822A priority patent/EP1267819B1/de
Priority to AU2001237433A priority patent/AU2001237433A1/en
Priority to JP2001566514A priority patent/JP2003526650A/ja
Priority to AT01909822T priority patent/ATE403470T1/de
Priority to DE50114194T priority patent/DE50114194D1/de
Publication of DE10013318A1 publication Critical patent/DE10013318A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE10013318A 2000-03-17 2000-03-17 Formulierung enthaltend Chinoxalinderivate Withdrawn DE10013318A1 (de)

Priority Applications (8)

Application Number Priority Date Filing Date Title
DE10013318A DE10013318A1 (de) 2000-03-17 2000-03-17 Formulierung enthaltend Chinoxalinderivate
PCT/EP2001/002517 WO2001068047A2 (de) 2000-03-17 2001-03-06 Zubereitung enthaltend chinoxalinderivate
US10/221,726 US20030207886A1 (en) 2000-03-17 2001-03-06 Preparation containing quinoxaline derivatives
EP01909822A EP1267819B1 (de) 2000-03-17 2001-03-06 Chinoxalinderivate, Zubereitungen diese enthaltend und Verwendung als UV-Filter
AU2001237433A AU2001237433A1 (en) 2000-03-17 2001-03-06 Preparation containing quinoxaline derivatives
JP2001566514A JP2003526650A (ja) 2000-03-17 2001-03-06 キノキサリン誘導体を含む調製物
AT01909822T ATE403470T1 (de) 2000-03-17 2001-03-06 Chinoxalinderivate, zubereitungen diese enthaltend und verwendung als uv-filter
DE50114194T DE50114194D1 (de) 2000-03-17 2001-03-06 Chinoxalinderivate, Zubereitungen diese enthaltend und Verwendung als UV-Filter

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10013318A DE10013318A1 (de) 2000-03-17 2000-03-17 Formulierung enthaltend Chinoxalinderivate

Publications (1)

Publication Number Publication Date
DE10013318A1 true DE10013318A1 (de) 2001-09-20

Family

ID=7635310

Family Applications (2)

Application Number Title Priority Date Filing Date
DE10013318A Withdrawn DE10013318A1 (de) 2000-03-17 2000-03-17 Formulierung enthaltend Chinoxalinderivate
DE50114194T Expired - Lifetime DE50114194D1 (de) 2000-03-17 2001-03-06 Chinoxalinderivate, Zubereitungen diese enthaltend und Verwendung als UV-Filter

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE50114194T Expired - Lifetime DE50114194D1 (de) 2000-03-17 2001-03-06 Chinoxalinderivate, Zubereitungen diese enthaltend und Verwendung als UV-Filter

Country Status (7)

Country Link
US (1) US20030207886A1 (US20030207886A1-20031106-C00044.png)
EP (1) EP1267819B1 (US20030207886A1-20031106-C00044.png)
JP (1) JP2003526650A (US20030207886A1-20031106-C00044.png)
AT (1) ATE403470T1 (US20030207886A1-20031106-C00044.png)
AU (1) AU2001237433A1 (US20030207886A1-20031106-C00044.png)
DE (2) DE10013318A1 (US20030207886A1-20031106-C00044.png)
WO (1) WO2001068047A2 (US20030207886A1-20031106-C00044.png)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022015A1 (de) * 2002-08-15 2004-03-18 Basf Aktiengesellschaft Verwendung von diketopiperazin-derivaten als photostabile uv-filter in kosmetischen und pharmazeutischen zubereitungen

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10111728A1 (de) * 2001-03-09 2002-09-12 Merck Patent Gmbh UV-Filter
CA2548172A1 (en) * 2003-12-04 2005-06-23 Vertex Pharmaceuticals Incorporated Quinoxalines useful as inhibitors of protein kinases
DE102004007966A1 (de) * 2004-02-18 2005-09-08 Merck Patent Gmbh Topische Zusammensetzung, enthaltend mindestens ein Aryloxim und Bisabolol
CN101595100B (zh) 2007-01-16 2014-06-11 普渡制药公司 作为orl-1配体的杂环取代的哌啶
JP5236297B2 (ja) * 2007-03-30 2013-07-17 富士フイルム株式会社 ヘテロ環化合物
EP3564240B1 (en) * 2007-08-31 2022-04-06 Purdue Pharma L.P. Piperidine intermediates
KR100889839B1 (ko) 2007-09-21 2009-03-20 한국화학연구원 신규 2-치환아미노알킬레닐옥시-3-치환페닐에티닐 퀴녹살린유도체
JP5250289B2 (ja) * 2008-03-31 2013-07-31 富士フイルム株式会社 紫外線吸収剤組成物
JP5244437B2 (ja) * 2008-03-31 2013-07-24 富士フイルム株式会社 紫外線吸収剤組成物
CN101644631B (zh) * 2008-08-06 2012-07-04 北京谊安医疗系统股份有限公司 注射泵故障检测装置
JP2010083980A (ja) * 2008-09-30 2010-04-15 Fujifilm Corp 固体高分子材料
TR201910781T4 (tr) * 2009-06-12 2019-08-21 Abivax Kanser tedavisi için yararlı bileşikler.
US10253020B2 (en) 2009-06-12 2019-04-09 Abivax Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging
AU2010289397B2 (en) 2009-09-03 2016-05-26 Bioenergenix Heterocyclic compounds for the inhibition of PASK
JP5604161B2 (ja) * 2010-04-12 2014-10-08 株式会社ファンケル 日焼け止め化粧料
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
JP5952829B2 (ja) * 2010-12-23 2016-07-13 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｃｒｔｈ２受容体調節剤としてのキノキサリン類およびアザ−キノキサリン類
WO2012094462A2 (en) 2011-01-05 2012-07-12 Bioenergenix Heterocyclic compounds for the inhibition of pask
CA2828349C (en) 2011-03-02 2019-05-21 John M. Mccall Heterocyclic compounds for the inhibition of pask
US8916561B2 (en) 2011-03-02 2014-12-23 Bioenergenix, Llc Substituted quinoxaline compounds for the inhibition of PASK
AR086744A1 (es) * 2011-06-28 2014-01-22 Nippon Soda Co Compuesto heterociclico conteniendo nitrogeno y fungicida para el uso en agricultura y jardineria
WO2013049272A2 (en) 2011-09-29 2013-04-04 Theraceutix, Llc Composition and method for treatment of symptoms associated with various skin conditions
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
RU2638540C1 (ru) 2012-04-24 2017-12-14 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы днк-пк
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
EP2757161A1 (en) 2013-01-17 2014-07-23 Splicos miRNA-124 as a biomarker of viral infection
HRP20211855T1 (hr) 2013-03-12 2022-03-04 Vertex Pharmaceuticals Incorporated Inhibitori dnk-pk
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
HRP20211839T1 (hr) 2013-07-05 2022-03-04 Abivax Biciklički spojevi korisni za liječenje bolesti uzrokovanih retrovirusima
PL3424920T3 (pl) 2013-10-17 2020-11-16 Vertex Pharmaceuticals Incorporated Kokryształy (S)-N-metylo-8-(1-((2'-metylo-4’,6'-dideutero-[4,5'-bipirymidyn]-6-ylo)amino)propan-2-ylo)chinolino-4-karboksyamidu i ich deuterowane pochodne jako inhibitory DNA-PK
JP6980385B2 (ja) 2014-03-26 2021-12-15 アステックス、セラピューティックス、リミテッドAstex Therapeutics Limited Ｆｇｆｒ阻害剤とｉｇｆ１ｒ阻害剤の組合せ
HUE053654T2 (hu) 2014-03-26 2021-07-28 Astex Therapeutics Ltd FGFR- és CMET-inhibitorok kombinációi a rák kezelésére
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
EP2974729A1 (en) 2014-07-17 2016-01-20 Abivax Quinoline derivatives for use in the treatment of inflammatory diseases
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
BR112018005637B1 (pt) 2015-09-23 2023-11-28 Janssen Pharmaceutica Nv Compostos derivados de quinoxalina, quinolina e quinazolinona,composições farmacêuticas que os compreende, e uso dos referidos compostos
KR20180052631A (ko) 2015-09-23 2018-05-18 얀센 파마슈티카 엔.브이. 비-헤테로아릴 치환된 1,4-벤조디아제핀 및 암의 치료를 위한 이의 용도
KR20190062485A (ko) 2016-09-27 2019-06-05 버텍스 파마슈티칼스 인코포레이티드 Dna-손상제 및 dna-pk 저해제의 조합을 사용한 암 치료 방법
CN111892597B (zh) * 2020-09-01 2023-07-25 山西天宏达安医药科技有限公司 一种喹喔啉基吡啶并吡嗪类化合物及其制备方法与应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3366668A (en) * 1965-10-23 1968-01-30 Gen Aniline & Film Corp 2, 2', 4'-tri-hydroxy benzophenone esters of dicarboxylic acids
US3862951A (en) * 1971-09-02 1975-01-28 Syva Co 2{40 Quinoldinyl glycerol compounds
FR2350096A1 (fr) * 1976-05-03 1977-12-02 Oreal Compositions destinees a la coloration de la peau a base de derives de la quinoxaline
DE3309400A1 (de) * 1983-03-16 1984-09-20 Wella Ag 3-amino-tetrahydro-1,3-thiazin-2,4-dione, ihre verwendung sowie diese verbindungen enthaltende hautbehandlungsmittel
US5057594A (en) * 1989-08-17 1991-10-15 Eastman Kodak Company Ultraviolet light-absorbing compounds and sunscreen formulations and polymeric materials containing such compounds or residues thereof
WO1994013647A1 (en) * 1992-12-15 1994-06-23 The Du Pont Merck Pharmaceutical Company (2-quinoxalinyloxy)phenoxypropanoic acids and related derivatives as anticancer agents
DE19506742A1 (de) * 1995-02-27 1996-08-29 Bayer Ag Verwendung von Chinoxalinen in Kombination mit Protease-Inhibitoren als Arzneimittel zur Behandlung von AIDS und/oder HIV-Infektionen
US5856329A (en) * 1995-06-28 1999-01-05 Allergan Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury
US5998423A (en) * 1996-10-08 1999-12-07 Therasys, Inc. Methods for modulating melanin production
WO2000061631A1 (en) * 1999-04-12 2000-10-19 Astrazeneca Ab Modified pentapeptide antagonists of the atrial natriuretic peptide clearance receptor
DE10111728A1 (de) * 2001-03-09 2002-09-12 Merck Patent Gmbh UV-Filter
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022015A1 (de) * 2002-08-15 2004-03-18 Basf Aktiengesellschaft Verwendung von diketopiperazin-derivaten als photostabile uv-filter in kosmetischen und pharmazeutischen zubereitungen

Also Published As

Publication number Publication date
JP2003526650A (ja) 2003-09-09
WO2001068047A3 (de) 2002-03-07
DE50114194D1 (de) 2008-09-18
AU2001237433A1 (en) 2001-09-24
EP1267819A2 (de) 2003-01-02
US20030207886A1 (en) 2003-11-06
WO2001068047A2 (de) 2001-09-20
EP1267819B1 (de) 2008-08-06
ATE403470T1 (de) 2008-08-15

Similar Documents

Publication Publication Date Title
EP1267819B1 (de) Chinoxalinderivate, Zubereitungen diese enthaltend und Verwendung als UV-Filter
EP1205475B1 (de) Flavonoidverbindungen zur Verwendung gegen oxidativen Stress und UV-Strahlung
EP1363594B1 (de) Kosmetische formulierung enthaltend flavonoid-derivate
EP1961453A2 (de) Benzyliden-ß-dicarbonylverbindungen als UV-Absorber
DE10030663A1 (de) UV-B-Filter
WO2000078277A1 (de) Mischungen aus mikropigmenten
DE10003786A1 (de) Galenische Formulierung
WO2001055128A1 (de) Benzofuranonderivate enthaltende formulierung zum schutz vor oxidativem stress
WO2004022015A1 (de) Verwendung von diketopiperazin-derivaten als photostabile uv-filter in kosmetischen und pharmazeutischen zubereitungen
ES2357177T3 (es) Derivados del ácido (4-oxo-4h-cromen-3-il)-hidroximetil)-fosfónico o del ácido (4-oxo-4h-cromen-3-il)-metil)fosfónico.
US20060222607A1 (en) Tricyclic quinoxaline and quinoline derivatives as UV filters
WO2007085568A1 (de) Verwendung von n,n-dimethyldecanamid in kosmetischen zubereitungen
EP2616040A1 (de) 2,2'-furoin-derivate und deren verwendung zur hautaufhellung
WO2015090850A1 (de) Verwendung von alkylamidothiazolen als antioxidans oder radikalfänger in kosmetischen oder dermatologischen zubereitungen
EP2720758A2 (de) Extrakte aus eugenia uniflora
DE10063867A1 (de) Kosmetische Lichtschutzzubereitungen
DE102006006115A1 (de) UV-Filter
DE10044985A1 (de) Verwendung von Ectoin oder Ectoin-Derivaten zum Schutz vor Allergenen und/oder Irritantien
EP1811989A1 (de) Zubereitung enthaltend oxidierte flavonoid-derivate
WO2013020624A1 (de) Extrakte aus tradescantia virginiana
WO2012065680A2 (de) Dihydroxyfumarsäure-derivate und deren verwendung zur hautaufhellung
DE10218540A1 (de) UV-A-Filter
DE102012008892A1 (de) Verwendung von Cyclohexanolethern mit antimikrobiellen Eigenschaften

Legal Events

Date Code Title Description
8139 Disposal/non-payment of the annual fee